Ependymoma

The case denies the binary classification of supratentorial ependymomas into ZFTA and YAP1 subtypes based entirely on the identity of 5' partner gene involved in the rearrangement. The findings elaborate the concept of molecular pathogenesis for YAP1-rearranged tumors.

P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2022 --> Dec 2030 | Trial primary completion date: Jan 2021 --> Dec 2029

Multiplexed imaging showed broad but heterogeneous HER2 expression across tumor states in both cases; in the MYCN-amplified tumor, this occurred alongside EGFR/MAPK-enriched proliferative niches, whereas the ZFTA-RELA tumor showed more diffuse organization without strong coupling of EGFR and proliferation. These findings provide early clinical evidence supporting HER2-directed ADCs in ependymoma and highlight the value of integrated molecular and spatial profiling in interpreting therapeutic response in rare CNS tumors.

P1/2, N=68, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

Maximal safe resection remains the cornerstone of management, with radiotherapy or chemotherapy reserved for selected cases. Despite potential morbidity, long-term survival and functional outcomes are favorable for many patients.

Although paraspinal peripheral nerve sheath tumors (including neurofibromas and schwannomas) occur frequently in the NF conditions, there is also a risk of intramedullary spinal cord tumors in people with NF1 and NF2-SWN. Here, we discuss the presentation and diagnosis of the various forms of NF, the intramedullary spinal cord tumors that occur in NF1 and NF2-SWN, and their diagnostic and treatment considerations.

The endoscopic transsphenoidal approach has proven to be a safe and highly effective method for achieving GTR in patients with PPTs. Spindle cell oncocytoma, with a higher level of vascularization than PC and GCT, poses a greater risk of surgical complicationsand may result in non-GTR.

P=N/A, N=370, Recruiting, Institut Claudius Regaud | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

This study emphasizes the heterogeneity of IHG and underscores the necessity for molecular surveillance in recurrent instances. The findings aid in refining diagnostic criteria and understanding the prognostic implications of genetic alterations in IHG.

This single-institution molecularly reclassified series highlights clinically relevant differences between intraventricular and extraventricular pediatric supratentorial ependymomas in presentation, surgical complexity, and treatment burden. Our findings support maximal safe resection as the central therapeutic strategy while emphasizing the value of integrated molecular diagnostics and prolonged surveillance, particularly in light of late recurrence and secondary neoplastic events.

However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis.

P1/2, N=68, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2043 --> Jun 2051